Abbott Q1 2020 Earnings Report
Key Takeaways
Abbott's Q1 2020 worldwide sales reached $7.7 billion, a 2.5% increase on a reported basis and a 4.3% increase on an organic basis. The company launched three new COVID-19 tests and is suspending its previously announced annual guidance for 2020 due to uncertainties related to the pandemic.
Worldwide sales increased by 2.5% on a reported basis and 4.3% on an organic basis.
Nutrition sales increased 6.3% on a reported basis and 7.3% on an organic basis, positively impacted by increased demand in late March.
Diagnostics sales decreased 0.8% on a reported basis but increased 0.7% on an organic basis, with Core Laboratory Diagnostics negatively impacted by lower routine testing volumes.
Abbott is suspending its previously announced annual guidance for 2020 due to uncertainties regarding the duration and impact of the coronavirus (COVID-19) pandemic.
Abbott
Abbott
Forward Guidance
Due to uncertainties regarding the duration and impact of the coronavirus (COVID-19) pandemic, Abbott is suspending its previously announced annual guidance for 2020.